| __timestamp | Protagonist Therapeutics, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 1860000 | 305409000 |
| Thursday, January 1, 2015 | 2963000 | 377080000 |
| Friday, January 1, 2016 | 6961000 | 432829000 |
| Sunday, January 1, 2017 | 11779000 | 496079000 |
| Monday, January 1, 2018 | 13697000 | 557616000 |
| Tuesday, January 1, 2019 | 15749000 | 658498000 |
| Wednesday, January 1, 2020 | 18638000 | 770456000 |
| Friday, January 1, 2021 | 27196000 | 840100000 |
| Saturday, January 1, 2022 | 31739000 | 944700000 |
| Sunday, January 1, 2023 | 33491000 | 1136600000 |
| Monday, January 1, 2024 | 1464300000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Vertex Pharmaceuticals Incorporated and Protagonist Therapeutics, Inc. have shown contrasting approaches to handling these costs. From 2014 to 2023, Vertex's SG&A expenses have surged by approximately 272%, reflecting its expansive growth strategy. In contrast, Protagonist Therapeutics has seen a more modest increase of around 1,700%, albeit from a much smaller base, indicating its aggressive scaling efforts.
While Vertex's SG&A expenses reached over $1.1 billion in 2023, Protagonist's expenses were significantly lower, highlighting the difference in their operational scales. This data provides a fascinating insight into how these companies prioritize their spending, with Vertex focusing on broad market penetration and Protagonist on strategic growth. Understanding these trends is essential for investors and industry analysts alike.
AbbVie Inc. vs Vertex Pharmaceuticals Incorporated: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Amgen Inc. and Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated and argenx SE: SG&A Spending Patterns Compared
Vertex Pharmaceuticals Incorporated vs Genmab A/S: SG&A Expense Trends
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Novavax, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
PTC Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: MorphoSys AG vs Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Wave Life Sciences Ltd.
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Celldex Therapeutics, Inc.